B-Cell Directed Therapies for Autoimmune Diseases Virtual Summit
October 14 - 15, 2020 - MA USHanson Wade
info@hansonwade.com
Phone:0000000000
Several clinical trials of B and plasma cell directed therapies are demonstrating posi-tive results across a broad range of non-oncological, immune mediated diseases including systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, multiple sclerosis, and Sjogren's syndrome. However, the vast potential of developing next generation B cell directed therapies remains challenging with limited fundamental knowledge on the role of B and plasma cell subtypes in health, autoimmunity and the wider immune system. Our virtual summit arrives as the first ever cross-disciplinary meeting for large pharma, biotech and academia. This forum is dedicated to harnessing the full therapeutic opportunity of numerous candidates directed against various B and plasma cell targets (incl. CD20, PI3K, BTK and more). Come armed with questions, ideas and ex-periences and together, take steps to develop the next generation of B cell directed therapies to improve immune mediated disease management, define effective combination treatment regimens and transform patient outcomes.